Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Shares Issued (2019 - 2025)

Historic Shares Issued for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $412000.0.

  • Beam Therapeutics' Shares Issued fell 4164.31% to $412000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 12364.61%. This contributed to the annual value of $5.6 million for FY2024, which is 9763.28% down from last year.
  • Latest data reveals that Beam Therapeutics reported Shares Issued of $412000.0 as of Q3 2025, which was down 4164.31% from $973000.0 recorded in Q2 2025.
  • Beam Therapeutics' 5-year Shares Issued high stood at $318.9 million for Q3 2021, and its period low was $240000.0 during Q2 2024.
  • In the last 5 years, Beam Therapeutics' Shares Issued had a median value of $22.4 million in 2022 and averaged $65.3 million.
  • Its Shares Issued has fluctuated over the past 5 years, first soared by 38136.12% in 2023, then crashed by 9977.7% in 2024.
  • Over the past 5 years, Beam Therapeutics' Shares Issued (Quarter) stood at $20.2 million in 2021, then skyrocketed by 57.54% to $31.9 million in 2022, then rose by 9.57% to $34.9 million in 2023, then tumbled by 91.48% to $3.0 million in 2024, then plummeted by 86.17% to $412000.0 in 2025.
  • Its Shares Issued stands at $412000.0 for Q3 2025, versus $973000.0 for Q2 2025 and $1.5 million for Q1 2025.